The rumen eukaryotome is a source of novel antimicrobial peptides with therapeutic potential by Onime, Lucy A. et al.
Aberystwyth University
The rumen eukaryotome is a source of novel antimicrobial peptides with
therapeutic potential
Onime, Lucy A.; Oyama, Linda B.; Thomas, Benjamin J.; Gani, Jurnorain; Alexander, Peter; Waddams, Kate E.;







Citation for published version (APA):
Onime, L. A., Oyama, L. B., Thomas, B. J., Gani, J., Alexander, P., Waddams, K. E., Cookson, A., Fernandez-
Fuentes, N., Creevey, C. J., & Huws, S. A. (2021). The rumen eukaryotome is a source of novel antimicrobial




Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are
retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the
legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or
research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
tel: +44 1970 62 2400
email: is@aber.ac.uk
Download date: 11. Dec. 2021
RESEARCH ARTICLE Open Access
The rumen eukaryotome is a source of
novel antimicrobial peptides with
therapeutic potential
Lucy A. Onime1†, Linda B. Oyama2†, Benjamin J. Thomas1,2†, Jurnorain Gani3, Peter Alexander2, Kate E. Waddams1,
Alan Cookson1, Narcis Fernandez-Fuentes1, Christopher J. Creevey2 and Sharon A. Huws2*
Abstract
Background: The rise of microbial antibiotic resistance is a leading threat to the health of the human population.
As such, finding new approaches to tackle these microbes, including development of novel antibiotics is vital.
Results: In this study, we mined a rumen eukaryotic metatranscriptomic library for novel Antimicrobial peptides
(AMPs) using computational approaches and thereafter characterised the therapeutic potential of the AMPs. We
identified a total of 208 potentially novel AMPs from the ruminal eukaryotome, and characterised one of those,
namely Lubelisin. Lubelisin (GIVAWFWRLAR) is an α-helical peptide, 11 amino acid long with theoretical molecular
weight of 1373.76 D. In the presence of Lubelisin, strains of methicillin-resistant Staphylococcus aureus (MRSA)
USA300 and EMRSA-15 were killed within 30 min of exposure with ≥103 and 104 CFU/mL reduction in viable cells
respectively. Cytotoxicity of Lubelisin against both human and sheep erythrocytes was low resulting in a
therapeutic index of 0.43. Membrane permeabilisation assays using propidium iodide alongside transmission
electron microscopy revealed that cytoplasmic membrane damage may contribute to the antimicrobial activities of
Lubelisin.
Conclusions: We demonstrate that the rumen eukaryotome is a viable source for the discovery of antimicrobial
molecules for the treatment of bacterial infections and further development of these may provide part of the
potential solution to the ongoing problem of antimicrobial resistance. The role of these AMPs in the ecological
warfare within the rumen is also currently unknown.
Keywords: Resistance, Antimicrobials, Antimicrobial peptide, Rumen, Microbiome, Eukaryotes, Eukaryotome
Background
Increasing bacterial resistance to existing antimicrobials
has led to a global human health crisis, which requires
exploration of alternatives to existing antibiotics [1–3].
The O’Neill report stated that by 2050, the burden of
deaths from antimicrobial resistance (AMR) will be
approximately 10 million lives each year [4]. The report
also noted that alternative strategies, such as phage ther-
apy, lysins, antibodies, and antimicrobial peptides
(AMPs) should be developed to combat the challenge of
multi-drug resistant bacteria [4].
AMPs are a distinct set of innate low molecular weight
molecules that are found in living organisms and have
broad spectrum activity against various bacterial species,
eukaryotes (fungi, protozoa) and enveloped viruses [5].
They act rapidly, curtailing early onset of resistance.
AMPs are classified according to their amino acid
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components and structure, which differ extensively. They
are, however, easy to identify because they share some key
characteristics, such as multiple cationic charges and high
hydrophobicity [6, 7]. Most AMPs engage with the bacter-
ial bilayer membrane, which means they can also be ef-
fective against inactive viable bacteria, giving them an
advantage over classic antibiotics that require prolonged
treatment to be effective against dormant bacteria [8]. In
eukaryotic cells, AMPs have been described as efficacious
molecules in the first line of chemical defence against
other microbial organisms [5, 9–11].
Although antimicrobials have been identified in some
eukaryotes [12–14], there is a need to intensify efforts
due to the increase in antimicrobial drug resistance.
Microbiomes possess an array of microorganisms offer-
ing a unique resource for antimicrobial discovery. The
rumen is an example of a complex microbiome made up
of eukaryotic microorganisms (anaerobic fungi and
protozoa), bacteria, viruses and methanogenic archaea,
all of which have intricate interrelationships. The rumen
microbiome has been shown to be a source of antimi-
crobials. Bacteriocins and bacteriocin-producing strains
have been isolated from ruminal bacteria [15, 16]. More
recently AMPs, Buwchitin, Lynronnes-1, 2 and 3, HG2
and HG4, coupled with non-ribosomal peptides were
identified from rumen bacterial metagenome libraries or
sequences [17–19]. The rumen derived antimicrobials
and AMPs identified so far have been mostly from pro-
karyotes, while the rumen eukaryotome remains largely
underexplored. In this study, we hypothesised that
rumen eukaryotes possess numerous AMPs, enabling
them to be able to compete in the rumen. We identified
and characterised novel AMPs from metatranscriptome
sequencing data obtained from the rumen eukaryotome.
To date, there are no published AMPs of rumen
eukaryotic origin to our knowledge.
Results
In silico mining of antimicrobial peptides and screening
against bacterial strains
Using bioinformatic analytic tools and online databases,
208 potential AMP candidates were identified from a
rumen eukaryotic metatranscriptomic sequence dataset
(Supplementary Table 1). These sequences formed the
basis of our AMP library to be screened. For the initial
high-throughput antimicrobial activity screening, pep-
tides were synthesised using the spot technique as it al-
lows for synthesis and screening of a high number of
peptides at an affordable cost. Peptide activity was inves-
tigated against Salmonella enterica serovar Typhimur-
ium SL1344, Escherichia coli K12, epidemic methicillin-
resistant Staphylococcus aureus-15 (EMRSA-15) and
Pseudomonas aeruginosa strain H1001 (containing the
lux operon resulting in bioluminescence when the
bacteria are viable). Thirteen of these 208 peptides
showed promising activity in the spot screen, one of
which - Lubelisin (GIVAWFWRLAR) was selected for
further testing. The coding sequence(s) (CDS) from the
mRNA transcripts in the dataset from which Lubelisin
(three transcripts) was derived are available in the Gen-
Bank database under accession numbers MK286889,
MK286890 and MK286891. A homology search in the
Antimicrobial peptide database APD3 [20] reveal that
Lubelisin has 50% similarity to peptide P15a identified
from rumen bacteria [18], 44% similarity to CcAMP1
(from the arthropod Coridius chinensis), 42.85% to
buCATHL4B (cathelicidin from Bubalus bubalis),
41.66% to Peptide 536_2 (predicted from medicinal leech
Hirudo medicinalis) and 38.46% to Tet037 (a synthetic
peptide-). Sequence alignment of Lubelisin and these top
five homologous AMP hits on the APD3 database using
Clustal [21] is included in Supplementary Table 1. The
sequences of transcripts of the parent protein from
which Lubelisin was derived were compared against the
MiBIG database [22] using multiple sequence alignment
(MUSCLE) [23] and sequence similarity clustering (CD-
HIT) [24] at 80 and 90% similarity thresholds and no
hits to known biosynthetic gene clusters could be re-
solved. The length of the Lubelisin transcripts (682, 688
and 724 bp) restricted analysis using other tools such as
antiSMASH [25] which require a minimum sequence
length of 1000 bp.
Determination of minimum inhibitory concentration (MIC)
and minimal bactericidal concentration (MBC)
The MICs of these 13 AMPs against a range of bacterial
pathogens were determined. Based on this MIC data
(Table 1), one AMP, namely Lubelisin, was chosen for
further characterisation due to it's low MIC values.
Lubelisin exhibited varying degrees of antibacterial activ-
ities against the microorganisms tested. It was particu-
larly more active against Gram-positive bacteria strains
with MIC range between 8 to 64 μg/mL (Table 1). Lube-
lisin had an MIC of 8 μg/mL and MBC of 32 μg/mL re-
spectively against S. aureus strains. It was also active
against E. coli K12 (MIC of 64 μg/mL, MBC 128 μg/mL)
and a sensitive hospital isolate of Acinetobacter bauman-
nii (MIC, 32 μg/mL, MBC 64 μg/mL). A higher MIC of
128 μg/mL was observed for drug resistant A. baumannii
isolates. Lubelisin was least active against Pseudomonas
aeruginosa strains PAO1 and H174 with MICs of
128 μg/mL and 256 μg/mL respectively.
AMP structure predictions and biophysical parameters
Lubelisin (GIVAWFWRLAR, molecular weight 1373.76)
is 11 amino acids (AAs) in length, is positively charged
(+ 2) and highly hydrophobic with 72% hydrophobic res-
idues, features, which are common characteristics of
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antimicrobial peptides (Fig. 1). Molecular modelling of
the peptide 3D structure based on a precomputed library
of short structural fragments assembled and sampled
using a Monte Carlo simulation revealed that Lubelisin
converges into an amphipathic α-helix with a clear pat-
tern of spatial segregation of hydrophobic versus
charged residues typical of many known antimicrobial
peptides (Fig. 1). Circular dichroism studies in different
solutions/environments and other methods, which give
the residue-specific information may be required to con-
firm the accuracy of the predicted structure upon pep-
tide interaction with membranes and how this affects
peptide activity.
Time-kill assays
To characterise the bactericidal or bacteriostatic activity
of Lubelisin, exponential-phase MRSA cells, EMRSA-15
and USA300 cells were challenged with a 3× MIC con-
centration of the peptide. Post-challenge viability was
assessed by determination of CFU/mL. Lubelisin at 3×
MIC was rapidly bactericidal against EMRSA-15 with
≥103 CFU/mL reduction in viable cells (Fig. 2a) and ≥
104 CFU/mL reduction in MRSA USA300 viable cells
(Supplementary Table 1) within 30 min of exposure to
the peptide. The comparator antibiotic, vancomycin at
3× MIC produced between ≥103 CFU/mL reduction in
the EMRSA-15 cells after 6 h, attributable to differences
in kill kinetics and mode of action [26].
Serial passage for selection of resistance
No resistant mutants were recovered after 26 days of ser-
ial passage of EMRAS-15 cells in the presence of sub-
MIC levels of Lubelisin (see daily MICs obtained in ser-
ial passage assay in Supplementary Table 1).
Membrane permeabilisation
Membrane permeabilisation ability of Lubelisin in
EMRSA-15 cells evaluated using the propidium iodide
method revealed that Lubelisin had a concentration
dependent membrane permeabilising effect (see mem-
brane permeabilisation for all concentration ranges in
Supplementary Table 1). Compared to CTAB, Lubelisin
at MIC concentration induced ~ 25% membrane
permeabilization in EMRAS-15 cells, and > 75% at 2×
and 4× MIC concentrations within a few minutes of ex-
posure (Fig. 2b). This may indicate that Lubelisin em-
ploys membrane permeabilisation in its antimicrobial
activity against the pathogen.
Haemolytic activity
The haemolytic activity of Lubelisin against human
RBC was assessed as an indication of cytotoxicity to-
wards mammalian cells. Lubelisin exhibited a concen-
tration dependent haemolysis (Fig. 2c) causing little
haemolysis at sub-MIC concentration and up to 90%
haemolysis at the highest concentration (512 μg/mL)
tested when compared to the control agent 0.1% Tri-
ton X-100 (Fig. 2c). At MIC concentration (8 μg/mL),
Fig. 1 Predicted 3D structure of Lubelisin. Main and side chains shown in ribbon and stick representation and coloured according to atom type:
Carbon, Oxygen and Nitrogen in green, red and blue respectively. N- and C termini and some residues also shown in two different orientations
rotated by 90 degrees respectively. Figure rendered using PyMol
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Lubelisin caused 4.8% haemolysis to human RBC
resulting in a low therapeutic index of 0.43. The
haemolytic activity of Lubelisin against sheep
erythrocytes was also concentration dependent with ~
10, 20 and 30% haemolyis at MIC, 2× and 3× MIC
concentrations respectively (Supplementary Table 1).
Fig. 2 Activity of Lubelisin: time dependent kill at 3× MIC concentration against EMRSA-15 cells (a); Membrane permeabilisation activity against
EMRSA-15 (b); haemolytic activity of Lubelisin against human erythrocytes at a range of concentrations (c). For a-c, data are expressed as mean ±
standard deviations from 3 (a, c) and 2 (b) independent replicates respectively, and if error bars cannot be seen, this is since they were smaller
than the symbols. Shaded area in (a) indicates limit of detection
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Transmission electron microscopy
Transmission electron micrographs (useful for visualis-
ing the interior sections of single cells) revealed varying
morphological changes to EMRSA-15 cells treated with
Lubelisin at 3× MIC concentration after 30 min expos-
ure to the AMP (Fig. 3). Compared to the untreated
control cells, observed to have intact cytoplasmic mem-
brane structures, changes to cell morphology including
‘emptying’ and/or ‘ghost cells’ effects were evident in
cells treated with Lubelisin, indicating potential mem-
brane disruption and subsequent loss of cytoplasmic
content (Fig. 3).
Discussion
Multi-drug-resistant microorganisms are increasing in
abundance resulting in high mortality rates and a global
human health threat. This challenge of increasing resist-
ance to known antimicrobials can, in part, be circum-
vented by discovery and development of novel
alternatives, including AMPs [4]. In this study, we used
computational in silico methods to bio-prospect for
AMPs within metatranscriptomic sequencing data ob-
tained from the rumen eukaryotic community. One cat-
ionic AMP, Lubelisin with promising antimicrobial
activity was selected and further characterised. Cationic
AMPs such as Lubelisin with amphipathic structures
and high hydrophobicity are known to be membrane-
active, with enhanced Gram-positive antibacterial activ-
ity and are linked to a reduction of peptide specificity
for Gram-negative bacteria [27–29]. Moreover, the posi-
tively charged surface of the peptide may interact with
bacterial membranes. Tryptophan residues in Lubelisin
may play a role in its antimicrobial activities, as they
have been observed to confer broad and effective anti-
microbial properties and interact with the bilayer inter-
facial region of bacterial membranes [30, 31]. Natural
antimicrobial peptides can present an amphipathic hel-
ical conformation although others, such as beta-hairpin,
hybrid beta/helical and other extended conformations,
are also possible [32]. Helical conformation is among the
most common among antimicrobial peptides [33]. Ex-
amples of helical antimicrobial peptides include spiniger-
ins [34], magainins [35], moricins [36] and others. Given
the regularity of alpha helices, the structural similarity
among any given pair of helices will be necessarily very
high, particularly on short helices, Sequence similarity of
Lubelisin indicated homology to known AMPs including
P15a (from rumen bacteria- 50%), CcAMP1 (from the
arthropod Coridius chinensis- 44%), buCATHL4B
(cathelicidin from Bubalus bubalis- 42.85%), Peptide
536_2 (predicted from medicinal leech Hirudo medicina-
lis- 41.66%) and Tet037 (a synthetic peptide- 38.46%).
The other 12 AMPs identified in the spot synthesis
screen showed poor activity when purified versions were
tested for antibacterial activity. This may indicate that
using the luminescent P. aeruginosa H1001 in a buffer
solution is very sensitive to favourable amino acid com-
binations within 4 h, but compared to short cationic
peptides in other studies [18], where the assay showed
very good correlation, here as also observed in other
studies [37], the results from the spot synthesis screen
could not be directly correlated to the antimicrobial ac-
tivity of most (12 of the 13) AMP candidates identified
from the spot screen.
Lubelisin demonstrated MICs between 8 to 64 μg/mL
against Gram-positive bacteria strains and higher MICs
between 32 to 256 μg/mL against Gram-negative strains.
Higher MICs were observed for clinical isolates of multi-
drug drug resistant A. baumanni strains (128 μg/mL)
compared to the sensitive isolate (32 μg/mL). The clin-
ical A. baumannii isolates exhibiting higher MICs for
Lubelisin are carbapenem resistant strains possessing an
inherent class D β-lactamase gene (blaOXA-51-like) as
well as the distantly related blaOXA-23 genes [38]. Al-
though colistin is the last resort for the treatment of in-
fections with carbapenem-resistant (CR) Gram-negative
Fig. 3 Transmission electron micrographs of Lubelisin against EMRSA-15 cells. Untreated and treated cells after 30 min exposure to Lubelisin at
3× MIC concentration. Scale bars are 500 nm as shown on micrographs
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bacteria including P. aeruginosa and particularly A. bau-
mannii (CRAB), strains resistant to colistin have been
isolated globally [39–41]. It has been shown that
lipopolysaccharide-deficient Gram-negative bacteria in-
cluding clinical isolates of A. baumannii can rapidly de-
velop resistance to polymyxin antibiotics by complete
loss of the initial binding target, the lipid A component
of lipopolysaccharide (LPS- considered to be essential
for the viability of Gram-negative bacteria) [40] follow-
ing mutation within one of the first three genes of the
lipid A biosynthesis pathway: lpxA, lpxC, and lpxD [42].
Modification of lipopolysaccharide (LPS) by upregulation
of the pmrCAB operon results in the synthesis and
addition of positively charged phosphoethanolamine to
the LPS. An increase in positive charge of the LPS leads
to a decrease in the binding between colistin (positive
charge) and lipid A (negative charge) of the LPS, thus
resulting in colistin resistance [42]. This modification
has been observed in all colistin-resistant A. baumannii
isolates, but none of the corresponding colistin-
susceptible isolates [43–45]. Like colistin, Lubelisin is
positively charged and membrane acting and so the poor
MICs observed for Lubelisin in these strains compared
to the sensitive strain may be indicative of a modifica-
tion in their LPS. This higher MIC in Gram-negative
MDR strains has also been observed in other rumen
microbiome derived AMPs [18].
Lubelisin demonstrated rapid antimicrobial activity
causing between ≥103 and ≥ 104 CFU/mL reduction in
viable cells within 30min against the Gram-positive bac-
teria, EMRSA-15 and MRSA USA300 respectively. This
rapid action induced by Lubelisin is common with many
cationic AMPs including colistin, avian β-defensins and
Lynronne-1 [18, 46] and it is thought that this reduces
the likelihood of resistance developing against the AMPs
although resistance to colistin in Gram-negative bacteria
has been widely reported [40]. Serial passage of EMRSA-
15 cells in the presence of sub-MIC levels of Lubelisin
failed to produce resistant mutants (MIC values
remaining within one to two-fold shifts), suggesting a
non-specific mode of action [47]. Lubelisin had a low
therapeutic index of 0.43 an indication that it may have
low bacterial specificity. Modifications to improve the
therapeutic index of Lubelisin will be needed to improve
its usefulness for the treatment of non-topical infections.
Well researched integrated approaches for developing
peptide analogues with desired characteristics (structur-
ally simple, broad spectrum antibacterial activity and
non-cytotoxic) [46] will be required to improve the
therapeutic application of Lubelisin.
Membrane permeabilisation of ~ 75% in EMRA-15
cells was observed when exposed to Lubelisin com-
pared to CTAB. A time-dependent increase in
permeabilization was observed from 0 to 120,
however, this did not increase significantly after 30
min, indicating a fast-action mode of Lubelisin. Sev-
eral morphological changes including disintegration of
the cytoplasmic membrane and emptying of cellular
content were observed in TEM micrographs of Lube-
lisin treated EMRA-15 cells. This may indicate that
loss of viability in Lubelisin treated EMRA-15 cells, is
induced by cytoplasmic membrane damage among
other factors, causing interference with the cell div-
ision mechanism of the bacteria and targeting intra-
cellular structures. Many studies have indicated that
amphipathicity of alpha-helical peptides (in which
hydrophobic residues interact with membrane lipid
components while hydrophilic regions either bind
with the phospholipid head groups or form the lumen
of a membrane pore) is a key characteristic required
for membrane permeabilization and consequently
antimicrobial activity [10]. The importance of these
peptides in the ecological interactions within the
rumen remain unknown.
Conclusions
The antimicrobial peptide Lubelisin characterised in this
study is novel and efficacious in in vitro experiments
against clinically relevant human pathogens, particularly
methicillin-resistant S. aureus strains, rendering them as
potential leads and/or templates for development of al-
ternative treatment strategies for infections caused by
these pathogens. The identification of Lubelisin also sup-
ports the hypothesis that rumen eukaryotes possess
AMPs and are a viable alternative resource for the dis-
covery of novel antimicrobials relevant in the fight
against multi-drug resistant bacteria.
Methods
Sample preparation and RNA extraction
We obtained metatranscriptomic data for the rumen eu-
karyotes from an experimental design previously re-
ported, whereby we analysed diversity (metataxonomy)
and function (metatranscriptomics) from fresh perennial
ryegrass attached bacteria (NCBI bioproject ID
PRJNA274256) [48]. Briefly, fresh perennial ryegrass was
incubated in the rumen of three cannulated, non-
lactating Holstein x Friesian cows, using the nylon bag
method and under home office licence. Two bags were
removed at 1, 2, 4, and 6 h post incubation, and residual
forage was washed and stored at − 80 °C. In order to ob-
tain metatranscriptome data for the polyA eukaryotic
fraction, rumen samples from the experiment were fro-
zen and ground to a fine powder under liquid nitrogen
before RNA was extracted using a hot phenol method
[49]. Essentially, aquaphenol (10 mL) was added to the
ground sample prior to incubation at 65 °C for 1 h.
Tubes were inverted before chloroform was added (5
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mL). Tubes were centrifuged (5000×g, 30 min, 20 °C) be-
fore upper phase was removed then the procedure was
repeated by addition of more chloroform (5 mL) and
centrifugation as described. Lithium chloride (2M final
concentration) was then added, to remove any contam-
inating DNA, and samples stored overnight at 4 °C. Sam-
ples were subsequently centrifuged (13,000×g, 30 min,
4 °C) and supernatant discarded, then the procedure was
repeated with addition of lithium chloride to ensure all
DNA was removed. Once the supernatant was discarded
the pellet was resuspended in ice cold 80% ethanol and
centrifuged (13,000×g, 15 min, 4 °C), this was repeated
twice before the pellet was air dried and resuspended in
molecular grade water. Absence of DNA in all sample
RNA extracts was checked using PCR as described in
Huws et al. (2016) [48], using non-barcoded primers and
subsequent agarose gel electrophoresis. Quality and
quantity of retrieved RNA was checked using the
Experion automated electrophoresis system and RNA
StdSens chips (Bio-rad, Hemel Hempstead, United
Kingdom).
RNA enrichment
The RNA was enriched for Polyadenylated mRNA
(eukaryotic fraction) using a Poly(A) Purist™ MAG kit
(Life Technologies, USA) (produced by eukaryote frac-
tion only), following the manufacturer’s guidelines; this
was repeated twice to minimise prokaryotic DNA and
rRNA carryover. An equal volume of 2X Binding Solu-
tion was added to each sample and mixed thoroughly
(thus doubling the initial sample volume). A mass of
Oligo (dT) MagBeads equivalent to the amount of RNA
was added to a clean tube, then captured and pulled out
of the storage solution using a magnetic stand (Thermo-
Fisher Scientific, USA). The storage buffer was removed
and discarded then Wash solution 1 added at a ratio of
500 μL per mg of beads. The tube was removed from the
stand and the beads resuspended, the tube was then put
back on the stand, the Magbeads captured and solution
removed. The RNA in binding solution was then added
to the beads, mixed thoroughly and they were then incu-
bated at 75 °C for 5 min. The tubes were then incubated
at RT for 1 h on a shaker. Next, the tubes were put back
into the magnetic stand to capture the beads and the
supernatant removed. The beads with bound RNA were
washed with Wash solution 1, mixed thoroughly and
then placed back on the magnetic stand. The solution
was then discarded, and the process repeated. Using
Wash Solution 2 the process was repeated a further two
times.
Finally, the Poly(A) RNA was recovered by removing
the tubes from the magnetic stand, adding 200 μL of
pre-heated RNA storage solution and mixing well. The
tubes were then placed back in the magnetic stand to
capture the beads, and the RNA in solution was re-
moved into a new tube. A further 200 μL of warm RNA
storage solution was added and the process repeated.
The Poly(A) RNA was then precipitated using 40 μL 5M
Ammonium Acetate, 1 μL Glycogen and 1.1 mL 100%
EtOH overnight at − 20 °C. The RNA was recovered by
centrifugation at 12,000 rpm for 30min and 4 °C. The
supernatant was discarded, and the tube centrifuged
again briefly to remove all remaining solution. The pellet
was washed using 1 mL 70% EtOH: vortexed briefly, cen-
trifuged at 12,000 rpm for 10min at 4 °C and super-
natant discarded. The RNA pellet was then resuspended
in 20 μL of the RNA Storage solution and stored at −
80 °C.
Eukaryotic 18S rRNA was further minimised using the
RiboMinus Plant Kit (Invitrogen, California, USA), ac-
cording to manufacturer protocols. Firstly 225 μL of
magnetic beads per sample was placed in a 1.5 mL
microcentrifuge tube and brought out of solution using
a magnetic stand, the storage buffer was discarded, and
the beads were washed twice using 225 μL of RNase-free
water and 60 μL of magnetic bead resuspension solution.
Once the remaining wash buffer had been discarded,
65 μL of magnetic beads were added to a fresh tube.
RiboGuard RNase Inhibitor solution (1 μL) was also
added per sample. To each tube, the following reagents
were added: 4 μL Ribo-Zero Reaction buffer, 20 μL RNA
sample, 10 μL Ribo-Zero Removal solution and RNase-
free water to a total volume of 40 μL. The samples were
then incubated at 68 °C for 10 min and at room
temperature for 5 min. Next, the washed magnetic beads
were added to the sample, vortexed and incubated at
room temperature for 5 min before placing at 50 °C for a
further 5 min. The samples were then placed on the
magnetic stand and the supernatant containing the de-
pleted RNA moved to a fresh tube.
Finally, 16S rRNA was further minimised using Ribo-
Zero rRNA removal kit (bacteria) (Illumina, California,
USA) according to manufacturer protocols. The previ-
ously purified RNA was added to 10 μL of RiboMinus™
Probe (15 pmol/μL) and 100 μL of Hybridization buffer
and incubated at 75 °C for 5 min. The sample was then
cooled in a 37 °C water bath over 30 min. The RiboMi-
nus™ Magnetic beads (750 μL) were placed into a 1.5 mL
microcentrifuge tube and set in the magnetic rack and
the storage buffer aspirated and discarded. Next, the
beads were washed twice using 750 μL DEPC- H2O be-
fore resuspension in 750 μL of Hybridization buffer.
Beads (250 μL) were then transferred into a new tube
and incubated at 37 °C whilst the remainder (500 μL)
were placed in the magnetic stand. The supernatant was
removed and discarded and then the beads resuspended
in 200 μL of hybridization buffer and incubated at 37 °C.
Next, the sample was added to 500 μL of beads, mixed
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and incubated at 37 °C for 15 min, after which the tubes
were placed onto the magnetic stand and the super-
natant moved to a fresh tube. The second aliquot of pre-
pared magnetic beads (250 μL) was set on the magnetic
rack, supernatant removed and discarded before adding
the beads to the previous supernatant containing the
purified RNA. After mixing and incubation at 37 °C for
15 min, the tube was placed onto the magnetic stand
and the supernatant moved to a fresh tube. An ethanol
(EtOH) precipitation was then used to purify the RNA.
Two volumes of cold EtOH and 2M ammonium acetate
were added, the solution mixed and placed at − 20 °C
overnight. The RNA was then recovered by centrifuga-
tion at 4 °C for 30 min at 13,000 rpm. The supernatant
was then gently removed and a further 1 volume of cold
70% EtOH added. The solution was then centrifuged
again at 4 °C for 10 min at 13,000 rpm and the process
repeated. The RNA was centrifuged once more at 4 °C
for 5 min at 13,000 rpm and any remaining supernatant
discarded. The pellet was then briefly air dried and re-
suspended in DEPC-H2O. The purified products were
then checked for purity and quantity using the Experion
automated electrophoresis system (Bio-Rad Laboratories,
UK).
Sequencing
The mRNA was prepared for sequencing using a Tru-
Seq stranded mRNA library prep kit (Illumina, Cali-
fornia, USA) following manufacturer guidelines.
Library sequencing was completed using the Illumina
HiSeq 2500 (Illumina, California, USA) 100 bp paired-
end sequencing. Sequencing data was quality checked
using FastQC (Version 0.69; Babraham Bioinformatics,
UK) and then trimmed using a sliding window trim
with Trimmomatic (version 0.36.0) [50, 51]. Sliding
window size was set at 4 bps and average quality re-
quired was set at 20. Assembly of sequence data was
carried out using Trinity (version 0.0.1) [52] at default
parameters. A metatranscriptomic approach was uti-
lised to obtain rumen eukaryotic sequences due to
the increased difficulties of binning rumen eukaryotic
sequences with confidence from shotgun metage-
nomic sequences. Sequences are deposited in the
Short Read Archive under Bioproject: PRJNA563675;
Biosample: SAMN12684929: HAN4BADXX.
In silico mining and prediction of antimicrobial peptides
Putative AMP candidates were identified from the qual-
ity checked and assembled metatranscriptomic data
using publicly available analysis tools including the Anti-
microbial Peptide Database (APD3) [20], the Antimicro-
bial Sequence Scanning System (AMPA) [53],
BACTIBASE [54] and the Collection of Anti-Microbial
Peptides modelling tools (CAMPR3) [55] to identify
sequences of interest and bioactive regions suitable for
further characterisation. A total of 208 potential AMPs
were predicted, which were then chemically spot synthe-
sized at ≥60% purity and screened for antimicrobial ac-
tivity as described below [56].
AMP structure predictions
Molecular modelling of the 3D structures of peptides
showing potential therapeutic potential was carried out
using the PEP-FOLD structural prediction method [57].
The best models for each peptide were selected based on
the OPEP force field [58] and the PEP-FOLD score. Pre-
dicted peptide structures were visualized using the
PyMOL v1.7.6 program [59]. Hydrophobicity (H) and
Hydrophobic moment (μH) were calculated by using the
program heliquest [60], as window size the whole length
of peptide was used in case of the 11 and 12mer pep-
tides, window size 12 for the 13mer peptides, where the
first window was reported.
Antibacterial activity screening of spot-synthesised AMPs
The dissolved (in sterile distilled water) spot synthesised
peptides in 96 well plates (Greiner Bio One Ltd., Stone-
house, UK), were screened against diluted overnight cul-
tures (final concentration at 5 × 105 Colony Forming
Units per millilitre (CFU/mL) of luminescent P. aerugi-
nosa H1001 as previously described [61]. Activity against
P. aeruginosa H1001 strain was assessed by lumines-
cence reading (excitation/emission spectra of 470/695
nm) using the Hidex Sense Plate Reader Software 0.5
pre-release (LabLogic, Sheffield UK). Activity against
non-luminescent strains (epidemic methicillin-resistant
S. aureus EMRSA-15, Salmonella Typhimurium and
Escherichia coli K12) was assessed by fluorescence read-
ings (excitation/emission spectra of 560/590 nm) after
the addition of resazurin dye (100 μM final concentra-
tion). Peptides that caused ≥75% reduction in fluores-
cence or luminescence relative to the growth controls
were selected as having antimicrobial activity. The Pep-
tides Extension Package of the MATLAB toolbox [62].
SciXMiner was used for the computational analysis [63].
Peptide synthesis
Pure peptide synthesis (> 95% purity) on resin was com-
pleted for peptides showing potential antibacterial activ-
ity from crude spot synthesis via Genscript Inc. USA,
using 9-fluorenylmethoxycarbonyl for solid phase pep-
tide synthesis. Quality analyses of the peptides were vali-
dated using high-performance liquid chromatography
and mass spectrometry (see Supplementary Table 1). All
pure AMPs were dissolved in sterile distilled water. The
antimicrobial activity of pure AMPs were ascertained
followed by cytotoxicity, resistance and mechanistic
studies as described below.
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Determination of minimum inhibitory concentration (MIC)
and minimal bactericidal concentration (MBC)
MICs against a range of clinically important Gram-
positive and Gram-negative bacteria strains including
methicillin-sensitive Staphylococcus aureus (MSSA)
RN4220 epidemic methicillin-resistant S. aureus-15
(EMRSA-15), methicillin-resistant S. aureus USA300
(MRSA USA300), Bacillus cereus, Enterococcus faecalis
JH2–2, Escherichia coli K12, Salmonella enterica serovar
Typhimurium SL1344, P. aeruginosa PAO1, and hospital
isolates of Acinetobacter baummannii were determined
in quadruplicate by a modified microdilution broth
method [64] with a final bacterial inoculum concentra-
tion of 5 × 105 CFU/mL utilised as the test organisms.
Cation-adjusted Mueller Hinton (MH) broth was innoc-
lated overnight with a single colony of the tested micro-
organisms, subsequently grown for 16–24 h with shaking
at 225 rpm, and further diluted in the same broth to a
final concentration of 5 × 105 CFU/mL. The bacterial
suspension was added to sterile U-bottomed 96-well
plates, and the peptides and control antibiotics to be
tested were dissolved in sterile distilled water and serially
diluted in the wells. The MICs were recorded as the low-
est peptide concentration that inhibited growth after in-
cubation for 18 h [65]. Minimal bactericidal
concentration (MBC, defined as the lowest concentra-
tion of compound that kills > 99.9% of bacteria cells)
assessed by colony forming units was determined by
plating serially diluted cultures from wells from the MIC
plates.
Time-kill assays
Time-dependent kill assays were adapted from standard
procedures [66] and were all performed as previously
using exponential-phase cultures of EMRA-15 MRSA
and USA300 grown in MHB (1 × 106 CFU/mL). The
peptide, Lubelisin was added at 3× MIC concentration.
Experiments were performed in triplicates, and CFU/mL
was calculated at different time points after overnight in-
cubation of inoculated agar plates (MHA) at 37 °C. Kill
curves were plotted with CFU/mL against time (h).
Serial passage for selection of resistance
To evaluate if populations of AMP-resistant bacteria
could be selected, cultures were continuously exposed to
Lubelisin for a duration of 26 days, as previously de-
scribed [67]. Briefly, broth microdilution susceptibility
testing was performed using a standard doubling-
dilution series of Lubelisin concentrations on Day 1. Fol-
lowing incubation of the cultures for 24 h, and determin-
ation of the MIC, the well that contained the highest
concentration of AMPs permitting growth was diluted
1:1000 in MHB and used to provide the inoculum for
the next MIC assay; this process was repeated daily for
26 days.
Membrane permeabilisation
Membrane permeabilisation was evaluated using the
propidium iodide assay as previously explained [68].
Briefly, logarithmic phase suspension of bacterial cul-
tures was prepared from overnight culture grown in MH
broth. Bacteria were pelleted by centrifugation for 5 min
at 4000 rpm and resuspended in sterile Phosphate Buff-
ered Saline (PBS) at about 109 bacteria/mL. Propidium
iodide was added to the bacterial suspension to a final
concentration of 30 μM and allowed to equilibrate for
15 min at 37 °C. This suspension (100 μL) was then
transferred into black 96-well plates already containing
100 μL of serially diluted peptides at the desired concen-
trations. Kinetics of fluorescence variations (excitation at
530 nm / emission at 590 nm) were then recorded using
a microplate reader over a 2-h period with incubation at
37 °C. Cetyl trimethylammonium bromide (CTAB) (at
300 μM) served as positive control giving 100% perme-
abilisation. The permeabilisation effect of Lubelisin was
expressed as the percentage relative fluorescence unit
(RFU) to the positive control, CTAB.
Haemolytic activity and therapeutic index measurement
The ability of Lubelisin to lyse erythrocytes was assessed
as previously described [17, 69]. Fresh human red blood
cells (RBC) (Cambridge Bioscience, UK) and defibrinated
sheep erythrocytes (Oxoid Ltd. Hampshire, UK) were
washed 3 times with PBS, centrifuged for 5 min at 500
rpm between each wash and resuspended to 4% (v/v) in
PBS. This mixture was dispensed in 96-well plates and
the peptide, Lubelisin was added to the mixture at a
range of concentrations (or at MIC, 2× MIC and 3×
MIC values for S. aureus strains (i.e., 8, 16 and 24 μg/mL
only for haemolytic activity against sheep erythrocytes).
The mixtures were incubated at 37 °C for 1 h. Plates
were then centrifuged for 5 min at 1000 rpm and the ab-
sorbance (OD450 nm) of the supernatant was measured
using the Synergy™ H4 Hybrid Multi-Mode reader (Bio-
Tek Swindon UK) to detect any haemoglobin release.
Readings from PBS only wells (0% cell lysis) were used
to normalise data from all other wells and 0.1% Triton
X-100 served as a positive control (representing 100%
cell lysis). The percentage of haemolysis was calculated
according to the equation: (A450 peptide solution − A450
PBS)/ (A450 0.1% Triton X-100 −A450 PBS) × 100. The
therapeutic index (T.I.) was calculated as the ratio of the
minimum haemolytic concentration ((MHC)- causing
5% haemolysis to human erythrocytes) to the minimum
inhibitory concentration (MICGM+) [46]. The MICGM+
was the minimum inhibitory concentration of the
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peptide against Gram-positive bacterial strains after the
geometric mean was calculated.
Transmission electron microscopy
Transmission electron microscopy was used to further
investigate the mode of action and the effect of Lubelisin
[70]. Briefly bacterial cells at mid-log phase were treated
with Lubelisin at 3× MIC concentration of the pathogen
for 30 min. The treated samples were then washed 3
times at 5000 rpm for 5 min with PBS and fixed with
2.5% glutaraldehyde (Agar Scientific Ltd), in 0.1 M so-
dium cacodylate buffer pH 7.4 (Agar Scientific Ltd) over-
night at 4 °C. The cells were fixed, processed, and
adsorbed onto Formvar/carbon-coated copper grids and
stained with 2% uranyl acetate (pH 4). Samples were
subsequently visualized on a Jeol 1010 transmission elec-
tron microscope (JEOL Ltd., Tokyo, Japan) operated at
80 kV and 30,000 ×magnifications. Images were re-
corded with a Kodak MegaPlus camera Model 1.4i, visu-
alized by analySIS 3.1 software and processed on ImageJ.
Statistical analysis
All comparisons were based on the mean ± standard de-
viation of the mean (SD). Differences between treatment
groups were analysed using two-way analysis of variance
(ANOVA) with the Bonferroni post-test method for
comparison between groups. Results were considered
significant when P values were < 0.05.
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